Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.46 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2463182 | 0.79 | MTNR1A (0.42) | MTNR1AMTNR1BMCHR2HSD11B1SMN1; SMN2 | |
| SCHEMBL11295469 | 0.78 | MTNR1A (0.53) | MTNR1AMTNR1BHSD11B1SMN1; SMN2 | |
| SCHEMBL11295099 | 0.77 | MTNR1A (0.55) | MTNR1AMTNR1BSMN1; SMN2 | |
| SCHEMBL14196062 | 0.76 | AR (0.44) | MTNR1AMTNR1B | |
| SCHEMBL11312993 | 0.75 | MEN1 (0.41) | MTNR1AMTNR1BHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL6399720 | 0.75 | MCHR2 (0.37) | MTNR1AMTNR1BMCHR2LMNABLM | |
| SCHEMBL6399852 | 0.75 | ALDH1A1 (0.41) | MCHR2SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL11316278 | 0.74 | MEN1 (0.40) | MTNR1AMTNR1BHSD11B1SMN1; SMN2LMNA | |
| SCHEMBL6400837 | 0.74 | ALDH1A1 (0.40) | SMN1; SMN2LMNA | |
| SCHEMBL5780440 | 0.74 | MCHR2 (0.35) | MTNR1AMTNR1BMCHR2LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1697334-A1 | HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | Warner-Lambert Company LLC (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | GRAHAM JAMES M | 2005-12-22 | — | — | US | disclosed |
| WO-2005056540-A1 | HETEROCYCLIC SUBSTITUTED INDANE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF SCHIZOPHRENIA | WARNER-LAMBERT COMPANY LLC (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-0005821-B1 | INDANAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1982-12-08 | — | — | EP | disclosed |
| EP-0005821-A1 | Indanamine derivatives, process for their preparation and medicaments containing them | Hokuriku Pharmaceutical Co.,Ltd (JP) | 1979-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282819-A1 | Heterocyclic substituted indane derivatives and related compounds for the treatment of schizophrenia | CHRM1, CHRM2, CHRM5 | MTNR1A 79/4885MTNR1B 71/4885MCHR2 381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.